Immunological monitoring of anticancer vaccines in clinical trials

OncoImmunology

Volumn 2, Issue 8, 2013, Pages

  Ogi, Chizuru ^a   Aruga, Atsushi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Cancer; Clinical trial; Immunological analysis; Immunotherapy; Regulatory science

Indexed keywords

CANCER VACCINE; CD45RO ANTIGEN; DASIPROTIMUT T; EMEPEPIMUT S; FALIMAREV; INSEGIA; M VAX; ONAMELATUCEL L; OTS 102; SIPULEUCEL T; SPECIFID; TERTOMOTIDE; THERATOPE; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; VELIMOGENE ALIPLASMID; VITESPEN;

BREAST CANCER; CANCER CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLORECTAL CANCER; COLORECTAL CARCINOMA; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EXPERIMENTAL DESIGN; HUMAN; IMMUNE RESPONSE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTE PROLIFERATION; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT ASSESSMENT; PATIENT MONITORING; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RECURRENT CANCER; RETROSPECTIVE STUDY; REVIEW; SURVIVAL RATE;

EID: 84885764622     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.26012     Document Type: Review

References (44)

1. Gooden MJM, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumourinfiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011; 105:93-103; PMID:21629244; http://dx.doi.org/10.1038/ bjc.2011.189
2. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306; PMID:22419253; http://dx.doi.org/10.1038/ nrc3245
3. Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012; 10:1; PMID:22214470; http://dx.doi.org/10.1186/1479-5876-10-1
4. Reynolds SR, Zeleniuch-Jacquotte A, Shapiro RL, Roses DF, Harris MN, Johnston D, Bystryn JC. Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma. Clin Cancer Res 2003; 9:657-62; PMID:12576432
5. Speiser DE, Rimoldi D, Batard P, Liénard D, Lejeune F, Cerottini JC, Romero P. Disease-driven T cell activation predicts immune responses to vaccination against melanoma. Cancer Immun 2003; 3:12; PMID:12962476
6. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, Nakajima A, Hirohashi S. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007; 13:902-11; PMID:17289884; http:// dx.doi.org/10.1158/1078-0432.CCR-06-2363
7. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58:49-59; PMID:18446337; http://dx.doi.org/10.1007/ s00262-008-0523-4
8. Ogi C, Aruga A. Clinical evaluation of therapeutic cancer vaccines. Hum Vaccin Immunother 2013; 9:1049-57; PMID:23454867; http://dx.doi. org/10.4161/hv.23917
9. FDA's homepage Vaccines, Blood & Biologics, Cellular & Gene Therapy Products, Approved Products. Available from http:// w w w. f d a . g o v / Bi o l o g i c sBl o o dVa c c i ne s / CellularGeneTherapyProducts/ApprovedProducts/ ucm210012.htm
10. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW. Integrated data from 2 randomized, doubleblind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115:3670-9; PMID:19536890; http://dx.doi.org/10.1002/ cncr.24429
11. Randazzo M, Terness P, Opelz G, Kleist C. Activespecific immunotherapy of human cancers with the heat shock protein Gp96-revisited. Int J Cancer 2012; 130:2219-31; PMID:22052568; http://dx.doi. org/10.1002/ijc.27332
12. Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, Mulders P, Zielinski H, Hoos A, Teofilovici F, et al.; C-100-12 RCC Study Group. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008; 372:145-54; PMID:18602688; http://dx.doi.org/10.1016/ S0140-6736(08)60697-2
13. Berd D, Sato T, Maguire HC Jr., Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 2004; 22:403-15; PMID:14691123; http://dx.doi.org/10.1200/JCO.2004.06.043
14. Sondak VK, Sabel MS, Mulé JJ. Allogeneic and autologous melanoma vaccines: where have we been and where are we going. Clin Cancer Res 2006; 12:2337s-41s; PMID:16609055; http://dx.doi. org/10.1158/1078-0432.CCR-05-2555
15. Therion Reports Results of Phase 3 PANVAC-VF Trial and Announces Plans for Company Sale. PR Newswire 28 June available from http://www. prnewswire.com/news-releases /therion-reportsresults-of-phase-3-panvac-vf-trial-and-announcesplans-for-company-sale-56997582.html
16. Finke LH, Wentworth K, Blumenstein B, Rudolph NS, Levitsky H, Hoos A. Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine 2007; 25(Suppl 2):B97-109; PMID:17916465; http://dx.doi. org/10.1016/j.vaccine.2007.06.067
17. Oncothyreon Inc. Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono. Press release; Mar 23, 2010.
18. Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, Bender JF, Gold DP, Ghalie RG, Stewart ME, et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol 2009; 27:3036-43; PMID:19414675; http://dx.doi. org/10.1200/JCO.2008.19.8903
19. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011; 29:2787-94; PMID:21632504; http://dx.doi.org/10.1200/ JCO.2010.33.3005
20. Fernandes LE, Gabri MR, Guthmann MD, Gomez RE, Gold S, Fainboim L, et al. NGcGM3 Ganglioside: a privileged target for cancer vaccines. Clinical and Development Immunology 2010; 2010: 814397; dx.doi.org/10.1155/2010/814397
21. Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, Thiberville L, D'addario G, Coens C, Rome LS, et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 2005; 23:6854-64; PMID:16192577; http://dx.doi.org/10.1200/JCO.2005.17.186
22. Gilliam AD, Watson SA. G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert Opin Biol Ther 2007; 7:397-404; PMID:17309331; http://dx.doi. org/10.1517/14712598.7.3.397
23. OncoTherapy Science, Inc. Press release. Feb 29, 2012.
24. Testori A, Richards J, Whitman E, Mann GB, Lutzky J, Camacho L, Parmiani G, Tosti G, Kirkwood JM, Hoos A, et al.; C-100-21 Study Group. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol 2008; 26:955-62; PMID:18281670; http://dx.doi. org/10.1200/JCO.2007.11.9941
25. Uyl-de Groot CA, Vermorken JB, Hanna MG Jr., Verboom P, Groot MT, Bonsel GJ, Meijer CJ, Pinedo HM. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 2005; 23:2379-87; PMID:15755632; http://dx.doi. org/10.1016/j.vaccine.2005.01.015
26. Bedikian AY, Del Vecchio M. Allovectin-7 therapy in metastatic melanoma. Expert Opin Biol Ther 2008; 8:839-44; PMID:18476795; http://dx.doi. org/10.1517/14712598.8.6.839
27. Pharmexa stops one of two Phase III trials. Drugs. com May 13, 2008 available from http://www.drugs. com/news /pharmexa-stops-one-two-phase-iii-trials-8180.html
28. Butts CA, Socinski MA, Mitchell P, Thatcher N, Havel L, Krzakowski MJ, et al. START: A Phase III study of L-BLP25 cancer immunotherapy for unresectable Stage III non-small cell lung cancer. J Clin Oncol 2013; 31:suppl; abstr 7500
29. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18:3894-903; PMID:11099318
30. Hsueh EC, Morton DL. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Semin Cancer Biol 2003; 13:401-7; PMID:15001158; http://dx.doi.org/10.1016/j. semcancer.2003.09.003
31. Morton DL, Foshag LJ, Hoon DSB, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216:463-82; PMID:1417196; http:// dx.doi.org/10.1097/00000658-199210000-00010
32. Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol 2006; 24:3107-12; PMID:16754937; http://dx.doi.org/10.1200/ JCO.2005.04.4289
33. Koç ON, Redfern C, Wiernik PH, Rosenfelt F, Winter JN, Carter WD, Gold DP, Stewart ME, Ghalie RG, Bender JF. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma. J Immunother 2010; 33:178-84; PMID:20145546; http://dx.doi.org/10.1097/CJI.0b013e3181bfcea1
34. Grant SC, Kris MG, Houghton AN, Chapman PB. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin. Clin Cancer Res 1999; 5:1319-23; PMID:10389914
35. Brett BT, Smith SC, Bouvier CV, Michaeli D, Hochhauser D, Davidson BR, Kurzawinski TR, Watkinson AF, Van Someren N, Pounder RE, et al. Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol 2002; 20:4225-31; PMID:12377966; http://dx.doi. org/10.1200/JCO.2002.11.151
36. Berd D, Maguire HC Jr., Schuchter LM, Hamilton R, Hauck WW, Sato T, Mastrangelo MJ. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 1997; 15:2359-70; PMID:9196151
37. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 2004; 22:4717-24; PMID:15483014; http://dx.doi.org/10.1200/ JCO.2004.06.003
38. Reddish MA, MacLean GD, Poppema S, Berg A, Longenecker BM. Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother 1996; 42:303-9; PMID:8706053; http://dx.doi. org/10.1007/s002620050287
39. Miles D, Roché H, Martin M, Perren TJ, Cameron DA, Glaspy J, Dodwell D, Parker J, Mayordomo J, Tres A, et al.; Theratope® Study Group. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 2011; 16:1092-100; PMID:21572124; http://dx.doi.org/10.1634/ theoncologist.2010-0307
40. Gilliam AD, Broome P, Topuzov EG, Garin AM, Pulay I, Humphreys J, Whitehead A, Takhar A, Rowlands BJ, Beckingham IJ. An international multicenter randomized controlled trial of G17DT in patients with pancreatic cancer. Pancreas 2012; 41:374-9; PMID:22228104; http://dx.doi. org/10.1097/MPA.0b013e31822ade7e
41. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29:610-8; PMID:21245428; http:// dx.doi.org/10.1200/JCO.2010.30.5425
42. Schuster SJ, Neelapu SS, Gause BL, Muggia FM, Gockerman JP, Sotomayor EM, et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results. J Clin Oncol 2009; 27:18s (suppl; abstr2)
43. Lee ST, Jiang YF, Park KU, Woo AF, Neelapu SS. BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma. Expert Opin Biol Ther 2007; 7:113-22; PMID:17150023; http:// dx.doi.org/10.1517/14712598.7.1.113
44. Shuster SJ, Neelapu SS, Gause BL, Muggia FM, Gockerman JP, Sotomayor EM, et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission. ASCO2009 Annual Meeting.